French MedTech startup RDS raises €14 million to industrialise MultiSense, a connected patch for remote patient monitoring

Strasbourg-based RDS, a French MedTech company, today announced a €14 million Series A funding round for its remote monitoring and wearable patch, in order to accelerate its development in France, Germany and the broader European market.

The SPI (Sociétés de Projets Industriels) fund, managed on behalf of the French state by Bpifrance, led the round, with Critical Path Ventures also taking a new stake. MACSF, Capital Grand Est and other historical investors also contributed.

With this financing, RDS will have raised a total of €28 million since its founding. The Series A €14 million comes on top of the €14 million in capital and non-dilutive financing provided by the French government, notably through the France 2030 investment plan.

“This investment gives us the means to ramp up our sales growth in Europe, consolidate the clinical and health economic value of MultiSense, and get ready for market launch in North America,” said Elie Lobel, CEO of RDS.

He added: “These funds mean we can roll out our solution more widely to hospitals, expand its positive impact for patients and care teams, and provide reliable, continuous, clinically validated remote monitoring to as many facilities as possible. The funds raised are a testament to our investors’ enduring confidence in this project and the team.”

Founded in 2020, RDS specialises in remote patient monitoring, developing, manufacturing and marketing MultiSense, a remote medical monitoring solution. RDS relies on an international team and collaborates with major research projects such as DARE and 5G-OR. Incubated at SEMIA/Quest for Health and accelerated by PariSanté Campus, it aims to redefine telemonitoring standards through patented technology and an eco-conscious approach.

The MultiSense solution combines a wearable patch with a cloud-based platform and associated support services. It continuously monitors six key parameters, including heart rate, respiratory rate and oxygen saturation.

From the outset, sustainability has been a core focus: the device can be cleaned, refurbished and reused to minimise its carbon footprint. MultiSense is designed to support the implementation of short-stay hospitalisation protocols, aiming to help reduce the average length of hospital stays, to ensure safer hospital discharge and to improve patients’ quality of life.

“France 2030 is proud to have supported this project since 2020 and to work today with SPI on the rapid industrialisation and effective deployment of the solution for the benefit of patients. RDS’ story clearly shows how France 2030 is capable of transitioning a project from the lab stage to becoming an international champion,” said Bruno Bonnell, Secretary General for Investment, in charge of France 2030.

RDS’ Series A fits into a broader surge of investment flowing into European HealthTech in 2025. According to our previous coverage, HealthTech was the most funded tech sector in Q1 2025 (bringing in €4.42 billion in private funding). Two relevant trends begin to rise when considering other funding rounds in this sector:

• Wearable/monitoring/device scale: ViCentra’s €72.4 million Series D round underscores how differentiated medical devices (in that case, insulin patch pumps) are attracting significant capital when they combine usability, regulatory readiness, and clinical integration.

• Imaging and diagnostic tools: Rounds such as PIUR IMAGING’s growth capital show that AI-augmented imaging and diagnostic devices are also drawing sustained investor interest, especially when bridging into new geographies.

Relative to these, RDS’ raise is moderate in size but meaningful, especially for a Series A in the MedTech hardware + clinical trials space. Its focus on scaling industrialisation, reimbursement, and European rollout is closely aligned with what investors have rewarded elsewhere.

“We are delighted to be supporting RDS in this critical phase of its development,” said Magali Joëssel, director of the SPI fund at Bpifrance. “This funding gives the company the means to become a leading player in post-operative remote monitoring through MultiSense, and a pioneer in the medicine of the future. By scaling the manufacturing of its solution, RDS fully embodies the principle of the SPI fund: funding the industrialisation of innovative technologies that will bring growth and jobs to France.”

Their clinically validated technology has already been rolled out in 15 hospitals across France, Belgium and Germany. In the last year, the device was added to the approved supplies list for RESAH and UniHA, leading public purchasing bodies for hospitals in France.

The company expects to create several hundred new jobs by 2035, bolstering its sales team to meet the demand for the MultiSense solution. The funds will also finance the industrialisation of the solution that is manufactured in France, with the aim of gradually ramping up production and refurbishing capacities.

Simultaneously, RDS will launch complementary clinical trials to support its applications for reimbursement in France and across Europe. The company is also preparing to initiate the FDA registration process, with a view to a US market launch in 2028.

“We believe that the key to transforming the healthcare system is useful innovation and industrial ambition,” said Nicolas Foessel of Critical Path Ventures. “With our investment in RDS, we are backing a team that combines technological excellence with clinical impact and a long-term vision for medicine, with emphasis on a more preventive, smoother and human approach. MultiSense exemplifies this positioning, enabling continuous monitoring and meeting patients’ particular needs away from the hospital setting.”

In parallel with this funding round, Laurent Monnin, senior investment director at Bpifrance, joins the company’s strategic board, as does Nicolas Foessel, representing Critical Path Ventures.

“The funding provided by SPI and Critical Path Ventures is a real asset for RDS, which will be able to ramp-up activities after a launch phase to which MACSF and Capital Grand Est have contributed,” said Jean-François Rax, partner at Capital Grand Est.

The post French MedTech startup RDS raises €14 million to industrialise MultiSense, a connected patch for remote patient monitoring appeared first on EU-Startups.